GW4064

Catalog No.S2782

For research use only.

GW4064 is an agonist of farnesoid X receptor (FXR) with EC50 of 65 nM in CV1 cell line and displays no activity at other nuclear receptors at concentrations up to 1 μM. GW4064 stimulates autophagy in MCF-7 cells.

GW4064 Chemical Structure

CAS No. 278779-30-9

Selleck's GW4064 has been cited by 21 publications

Purity & Quality Control

Choose Selective FXR Inhibitors

Other FXR Products

Biological Activity

Description GW4064 is an agonist of farnesoid X receptor (FXR) with EC50 of 65 nM in CV1 cell line and displays no activity at other nuclear receptors at concentrations up to 1 μM. GW4064 stimulates autophagy in MCF-7 cells.
Targets
FXR [1]
(CV1)
65 nM(EC50)
In vitro

GW 4064 is a full agonist with EC50 values of 80 and 90 nM, respectively, in CV-1 cells transfected with mouse and human FXR expression vectors and an established reporter gene. There is no activity of GW 4064 on other nuclear receptors, including the retinoic acid receptor, at concentrations up to 1 μM. Thus, GW 4064 is a potent and selective nonsteroidal FXR agonist. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 M1;scWZ2dmO2aX;uJIF{e2G7 NHztc3NC\2:waYP0bYMh[WO2aY\peJkh[XRiRmjSJIlvKEiHS{K5N{Bk\WyuczDifUBISUx2IITyZY5{[WO2aY\heIlwdiCjY4Tpeol1gSxiRVO1NEA:KDBwMEeg{txONg>? MmjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd{OUK2NVAoRjF5MkmyOlExRC:jPh?=
CV1 NXjIWoZHTnWwY4Tpc44h[XO|YYm= NGnZdIhC\2:waYP0JIFkfGm4aYT5JIF1KE[[UjDlfJBz\XO|ZXSgbY4h[W[{aXPhckBoemWnbjDtc45s\XliQ2[xJINmdGy|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIhfHKjboPp[Y51KHS{YX7z[oVkfGmxbjDhd5NigSxiRVO1NEA:KDBwME[1JO69VS5? M4C4bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkKxOVI{Lz5zOE[yNVUzOzxxYU6=
CV1 M136VWZ2dmO2aX;uJIF{e2G7 M1jVZ2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gSnhTKHS{YX7z[oVkfGWmIHnuJIFnemmlYX6g[5Jm\W5ibX;ub4V6KEOYMTDj[YxteyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmVidILhcpNq\W62IITyZY5{\mWldHnvckBie3OjeTygSWM2OCB;IECuNFY2KM7:TT6= M{HUWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEGwOFYxLz5zOUSxNFQ3ODxxYU6=
CV1 MVvGeY5kfGmxbjDhd5NigQ>? NXfwXpFiUW6lcnXhd4UhcW5iaIXtZY4hTliULX3l[IlifGWmIITyZY5{cWWwdDD0doFve2O{aYD0bY9vKG:oIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SC2cnHud4Zm[3SnZDDpckBi\nKrY3HuJIdz\WWwIH3vcotmgSCFVkGgZ4VtdHNuIFXDOVAhRSByLkC2OUDPxE1w NWrPXZNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1PFY4PjlpPkG5OVg3PzZ7PD;hQi=>
HEK293 MYrGeY5kfGmxbjDhd5NigQ>? M3juUGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6g[pVtdCCuZX7neIghTliUIITyZY5{\mWldHXkJIlvKEiHS{K5N{Bk\WyuczDjc4V5eHKnc4PpcocheFSUZYjE[ZN1N3CJTELwdo9ud3SxcjDhd5Nme3OnZDDhd{BtfWOrZnXyZZNmKGGldHn2bZR6KGK7IHTpdoVkfCC{ZYDvdpRmeiClZXzseYxieiCjc4PhfUwhTUN3MDC9JFAvODNizszNMi=> M3Xwd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkO4Nlc5Lz5{ME[zPFI4QDxxYU6=
HEK293 MnrISpVv[3Srb36gZZN{[Xl? MkHIRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDHV3Qu\nW|ZXSgSnhTKEyERDDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHPv[ZhxemW|c3nu[{BISUx2LVTORUBjcW6maXeg[I9u[WmwIHHu[EBxTlKudXOgZpkhdWGvbXHsbYFvKG:wZT3ofYJzcWRiYYPzZZktKEWFNUCgQUAxNjB|NTFOwG0v M3;QOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkO4Nlc5Lz5{ME[zPFI4QDxxYU6=
CV-1 NIDVboVHfW6ldHnvckBie3OjeR?= MUjB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIF\YVkBNSkRiaXX4dJJme3OnZDDpckBud26tZYmgR3YuOSClZXzsd{Bie3Onc4Pl[EBieyC2cnHud4FkfGm4YYTpc44hd2ZibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGW6cILld5Nqd25uIFXDOVAhRSByLkC2OUDPxE1w NUDTT2FrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyOVYxODVpPkKxNlU3ODB3PD;hQi=>
CV1 M13oZmZ2dmO2aX;uJIF{e2G7 M17Z[WFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gSnhTKEyERDD0doFve2[nY4Tl[EBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDDWlEh[2WubIOgZYZ1\XJib4\ldo5q\2i2IHnuZ5Vj[XSrb36gZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxKD1iMD6wOlUh|ryPLh?= NFnMe4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi5NFM2Pid-MkG4PVA{PTZ:L3G+
HEK293 NVLaeHFWTnWwY4Tpc44h[XO|YYm= MU\B[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIILlZ49u[mmwYX70JGZZWiCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGOxZYjwdoV{e2mwZzDDUXguT0GONF6gZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxKD1iMD6wO{DPxE1w NUPvXHZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1PFM3OTdpPkKyOVg{PjF5PD;hQi=>
HEK293 MU\GeY5kfGmxbjDhd5NigQ>? Mn3WRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDGXHIh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTBiPTCwMlAzPiEQvF2u NIPtUZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwOVY5QCd-MkWzNFU3QDh:L3G+
CV1 M3WwXGZ2dmO2aX;uJIF{e2G7 MWDB[49vcXO2IHHjeIl3cXS7IHH0JGZZWiBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnueI8h[W[{aXPhckBoemWnbjDtc45s\XliQ2[xJINmdGy|IHHzd4V{e2WmIHHzJIxq\2GwZD3t[YRq[XSnZDD0doFve2O{aYD0bY9vKGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKvJJRz[W6|aXXueEB1emGwc3\lZ5Rqd25iYYPzZZktKEWFNUCgQUAxNjB4NTFOwG0v M1q4[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEm5PFg{Lz5{NUS5PVg5OzxxYU6=
HeLa MUHGeY5kfGmxbjDhd5NigQ>? MUSyOEBpenN? NILiZXBC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIZ2dGxibHXu[5RpKE[[UjDlfJBz\XO|ZXSgbY4hUGWOYTDj[YxteyClb4TyZY5{\mWldHXkJJdqfGhicGPHOU1pfW2jbjDSXHIh[W[2ZYKgNlQhcHK|IHL5JGR2[WxvR3zvJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwNUGg{txONg>? M{TkOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO0NlI4Lz5{NUmzOFIzPzxxYU6=
HEK293 M2DHcWZ2dmO2aX;uJIF{e2G7 NX3QVnVXSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBHYFJidILhcpNn\WO2ZXSgbY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJJRz[W6|Y4LpdJRqd26jbDDhZ5Rqfmm2eTDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkO3N{DPxE1w M1vmR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4NVQ1Lz5{NkW2PFE1PDxxYU6=
HEK-293 NIXaeo5HfW6ldHnvckBie3OjeR?= NX2zXXBpSWexbnnzeEBi[3Srdnn0fUBifCCFLYTldo1qdmGuIFfhcFQufGGpZ3XkJIh2dWGwIF\YVkApOTh5IITvJFQ4OiC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJGhGUy1{OUOgZ4VtdHNiY3:t[ZhxemW|c3nu[{BxTlKudXOgZpkhdWGvbXHsbYFvKG:wZTDofYJzcWRiYYPzZZktKEWFNUCgQUAxNjB|NTFOwG0v NFr1[o89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{K2PFY6Pid-MkeyOlg3QTZ:L3G+
insect cells NWPH[HVrTnWwY4Tpc44h[XO|YYm= NXHHPIl[OSCqch?= MXvB[49vcXO2IHHjeIl3cXS7IHH0JJJm[2:vYnnuZY51KGi3bXHuJGdUXC22YXfn[YQhTliUIHzp[4Fv\CCkaX7kbY5oKGSxbXHpckApOTl|IITvJFQ4OiC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKGmwc3XjeEBk\WyuczDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiaX70[ZJi[3Srb36ge4l1cCCkaX;0bY4hdGGkZXzs[YQhW1KFLUGgZYZ1\XJiMTDodkBjgSCKVGLGJIF{e2G7LDDFR|UxKD1iMD6wNVkh|ryPLh?= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2OEiwOkc,OjlzNEi4NFY9N2F-
HEK293T Ml3aSpVv[3Srb36gZZN{[Xl? MYSyOEBpenN? NXHIbpI4SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBHYFJiZYjwdoV{e2WmIHnuJGhGUzJ7M2SgZ4VtdHNiYYPz[ZN{\WRiYYOgRnNGWCCycn;tc5RmeiCmcnn2[Y4h[2WubIXsZZIhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JIFnfGW{IEK0JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUCgQUAxNjB7NTFOwG0v NHL5UlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0PFgxPid-MkmxOFg5ODZ:L3G+
HepG2 MUnGeY5kfGmxbjDhd5NigQ>? MV2xJJVO M1r0S|E5KGi{cx?= M1fEWWRm[3KnYYPlJIlvKEO\UEfBNUBo\W6nIHX4dJJme3Orb36gbY4hcHWvYX6gTIVxTzJiY3XscJMh[XRiMTD1UUBi\nSncjCxPEBpenNiYomgVnQuWEOU NYe5blhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5OlM{PzFpPkG3PVY{OzdzPD;hQi=>
Caco-2 MWfGeY5kfGmxbjDhd5NigQ>? M1zJNFEhfU1? MVO2JIRigXN? MUDBZ5RqfmG2aX;uJI9nKEmEQVLQJIdmdmViZYjwdoV{e2mxbjDpckBpfW2jbjDDZYNwNTJiY3XscJMh[XRiMTD1UUBi\nSncjC2JIRigXNiYomgVnQuWEOU NHTvUGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m2N|M4OSd-MUe5OlM{PzF:L3G+
HepG2 M1nGUmZ2dmO2aX;uJIF{e2G7 MkL6NUB2VQ>? M3vkUVE5KGi{cx?= M3vieWFkfGm4YYTpc44hd2ZiQmPFVEBo\W6nIHX4dJJme3Orb36gbY4hcHWvYX6gTIVxTzJiY3XscJMh[XRiMTD1UUBi\nSncjCxPEBpenNiYomgVnQuWEOU MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl4M{O3NUc,OTd7NkOzO|E9N2F-
Huh7 MnzKSpVv[3Srb36gZZN{[Xl? NG[0N5gyKHWP MX[xPEBpenN? Mn;4RYN1cX[jdHnvckBw\iCVSGCg[4Vv\SCneIDy[ZN{cW:wIHnuJIh2dWGwIFj1bFch[2WubIOgZZQhOSC3TTDh[pRmeiBzODDodpMh[nliUmStVGNT M2TyPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OU[zN|cyLz5zN{m2N|M4OTxxYU6=
Huh7 MV3GeY5kfGmxbjDhd5NigQ>? M3vUOVEhfU1? NWXmfZVYOThiaILz NIrxcG5C[3SrdnH0bY9vKG:oIFLTSXAh\2WwZTDlfJBz\XO|aX;uJIlvKGi3bXHuJGh2cDdiY3XscJMh[XRiMTD1UUBi\nSncjCxPEBpenNiYomgVnQuWEOU MlnwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7NkOzO|EoRjF5OU[zN|cyRC:jPh?=
HepG2 MUHGeY5kfGmxbjDhd5NigQ>? NFG4ZYoyOCC3TR?= MVLJcoR2[3Srb36gc4YhTliULX3l[IlifGWmIGPIVEBuWk6DIHX4dJJme3Orb36gbY4he2W{dX2td5Rien[nZDDoeY1idiCKZYDHNkBk\WyuczDheEAyOCC3TTDt[YF{fXKnZDDh[pRmeiCxdnXycolocHRiaX7jeYJifGmxbjDifUByWEOUIHHuZYx6e2m| MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN5Mki0NEc,Ojd|N{K4OFA9N2F-
HepG2 NX7ZbXlFTnWwY4Tpc44h[XO|YYm= NGSyU2wyOCC3TR?= MX6xNEBucW6| NFSxNllKdmS3Y4Tpc44hd2ZiRmjSMY1m\GmjdHXkJGFsfC2yaH;zdIhwenmuYYTpc44h[XRiU{S3N{B{cXSnIHnuJJNmenWvLYP0ZZJ3\WRiaIXtZY4hUGWyR{KgZ4VtdHNiYYSgNVAhfU1ibXXhd5Vz\WRiYX\0[ZIhOTBibXnud{BjgSC5ZYP0[ZJvKGKub4SgZY5idHm|aYO= NIexSW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O3Nlg1OCd-MkezO|I5PDB:L3G+
HepG2 NFTNdXRHfW6ldHnvckBie3OjeR?= NGXNbnAyOCC3TR?= MX6xNEBucW6| NV;3bHFRUW6mdXP0bY9vKG:oIF\YVk1u\WSrYYTl[EBCc3RvcHjvd5Bpd3K7bHH0bY9vKGmwIIPldpVuNXO2YYL2[YQhcHWvYX6gTIVxTzJiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gS3NMNTOkZYThMZBpd3OyaH;yfYxifGmxbjDheEAyOCC3TTDt[YF{fXKnZDDh[pRmeiBzMDDtbY5{KGK7IIfld5Rmem5iYnzveEBidmGueYPpdy=> MkLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|N{K4OFAoRjJ5M{eyPFQxRC:jPh?=
HepG2 NXu1fWdoTnWwY4Tpc44h[XO|YYm= MoPxNVAhfU1? M{DueGFkfGm4YYTpc44hd2ZiRmjSJIlvKGi3bXHuJGhmeEd{IHPlcIx{KGG|c3Xzd4VlKGG|IIXwdoVofWyjdHnvckBw\iCVSGCgcXJPSSCneIDy[ZN{cW:wIHH0JFExKHWPIHL5JHJVNVCFUjDt[ZRpd2R? M4HwN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEOxOlE5Lz5|MECzNVYyQDxxYU6=
HepG2 M2rHPGZ2dmO2aX;uJIF{e2G7 MVyxNEB2VQ>? MUXBZ5RqfmG2aX;uJI9nKE[[UjDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YhTliUIH3SUmEh\XiycnXzd4lwdiCjdDCxNEB2VSCkeTDSWE1RS1JibXX0bI9l Ml\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{G2NVgoRjNyMEOxOlE5RC:jPh?=
HepG2 MnzESpVv[3Srb36gZZN{[Xl? NEDxVIgyOCC3TR?= MYTBZ5RqfmG2aX;uJI9nKE[[UjDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmb4fudoVofWyjdHnvckBw\iCVUlXCVE0y[yCvUl7BJIV5eHKnc4Ppc44h[XRiMUCgeW0h[nliUmStVGNTKG2ndHjv[C=> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB|MU[xPEc,OzByM{G2NVg9N2F-
3T3L1 MVvGeY5kfGmxbjDhd5NigQ>? MoP1NVAhfU1? MYjS[YR2[3Srb36gbY4hdGmyaXSgZYNkfW23bHH0bY9vKGmwIH3veZNmKDOWM1yxJINmdGy|IHH0JFExKHWPIHL5JG9qdCCUZXSgU{B{fGGrbnnu[{1j[XOnZDDhZpNwemKjbnPlJI1mfGixZDDy[YxifGm4ZTD0c{Bkd262cn;s MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2Mkm1O{c,OzB|NEK5OVc9N2F-
Assay
Methods Test Index PMID
Western blot PTEN / p-AKT / AKT ; p-EGFR / EGFR / p-ERK / ERK / p-Src / Src ; SOCS3 / p21 / p-STAT3 / STAT3 25187826 23119029 26416445
Growth inhibition assay Cell proliferation 25187826
In vivo Pharmacokinetic analysis in rats shows that GW 4064 possesses an oral bioavailability of 10% with a t1/2 = 3.5 h. Fisher rats are dosed with GW 4064 by oral gavage. After 7 days, a dose-dependent lowering of serum triglycerides is observed in the rats receiving GW 4064, with an ED50 = 20 mg/kg. [2]

Protocol (from reference)

Animal Research:

[2]

  • Animal Models: Fisher rats
  • Dosages: 0-100 mg/kg
  • Administration: Orally, b.i.d.

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(184.21 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
0.5% methylcellulose
For best results, use promptly after mixing.

11 mg/mL

Chemical Information

Molecular Weight 542.84
Formula

C28H22Cl3NO4

CAS No. 278779-30-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)C1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)COC3=CC(=C(C=C3)C=CC4=CC(=CC=C4)C(=O)O)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy GW4064 | GW4064 supplier | purchase GW4064 | GW4064 cost | GW4064 manufacturer | order GW4064 | GW4064 distributor